| Literature DB >> 10519944 |
W A Keitel1, K E Kester, R L Atmar, A C White, N H Bond, C A Holland, U Krzych, D R Palmer, A Egan, C Diggs, W R Ballou, B F Hall, D Kaslow.
Abstract
The safety and immunogenicity of 2 yeast-derived, blood-stage malaria vaccines were evaluated in a phase l trial. Healthy adults were given 2 or 3 doses of alum-adsorbed vaccine containing the 19 kDa carboxy-terminal fragment of the merozoite surface protein-1 (MSP-1(19)) derived from the 3D7 or the FVO strain of Plasmodium falciparum fused to tetanus toxoid T-helper epitopes P30 and P2. The first 2 doses of MSP-1(19) were well tolerated. Hypersensitivity reactions occurred in 3 subjects after the third dose of MSP-1(19), including bilateral injection site reactions in 2 (one with generalized skin rash), and probable histamine-associated hypotension in 1. Serum antibody responses to MSP-1(19) occurred in 5/16, 9/16 and 0/8 subjects given 20 microg of MSP-1(19), 200 microg of MSP-1(19), and control vaccines (hepatitis B or Td), respectively. Both MSP-1(19) vaccines were immunogenic in humans, but changes in formulation will be necessary to improve safety and immunogenicity profiles.Entities:
Mesh：
Substances：
Year: 1999 PMID： 10519944 DOI： 10.1016/s0264-410x(99)00221-2
Source DB: PubMed Journal: Vaccine ISSN： 0264-410X Impact factor: 3.641